AstraZeneca PLC (OTCMKTS:AZNCF) Short Interest Up 13.7% in October

AstraZeneca PLC (OTCMKTS:AZNCF) saw a large increase in short interest in October. As of October 31st, there was short interest totalling 42,200 shares, an increase of 13.7% from the October 15th total of 37,100 shares. Based on an average daily volume of 2,500 shares, the days-to-cover ratio is currently 16.9 days.

Hedge Funds Weigh In On AstraZeneca

A hedge fund recently bought a new stake in AstraZeneca stock. Eagle Bay Advisors LLC acquired a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,001 shares of the company’s stock, valued at approximately $156,000. Institutional investors and hedge funds own 40.87% of the company’s stock.

AstraZeneca Stock Performance

Shares of OTCMKTS AZNCF opened at $127.96 on Friday. The stock’s fifty day moving average is $149.51 and its 200 day moving average is $155.43. AstraZeneca has a 52 week low of $118.16 and a 52 week high of $175.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.